atopic dermatitis

target reach ladder climb meet win beat competition
Biotech

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Analysts doubled their peak sales forecast to $5.2 billion in the belief zumilokibart will become the first-line treatment for most eczema patients.
Nick Paul Taylor Mar 23, 2026 9:00am
target reach ladder climb meet win beat competition

Pfizer ramps up plans for trispecific after ph. 2 eczema win

Mar 9, 2026 9:10am
warning sign

New cancer cases prompt Kyowa to shutter rocatinlimab trials

Mar 3, 2026 11:00am
Close up shot of the target from a dart game

Lynk sees ph. 3 eczema win as proof of JAK inhibitor's potential

Mar 2, 2026 8:55am
Completing steps towards success checkmark on cubes symbolizing progress

Nektar eczema asset 'checked all of the boxes' in phase 2

Feb 10, 2026 10:55am
Graphic image of an arrow nailing the bullseye of a target

Evommune's Dupixent-like eczema data drive 75% stock rally

Feb 10, 2026 9:31am